Sanofi is expanding its insulin portfolio to include the new inhaled insulin, Affreza. While it may not perform in the market at the scale of Lantus, I, for one, am glad that Sanofi is doing this. Five years ago a small company called VeroScience came out with a new …
Read More »Yearly Archives: 2014
First SGLT-2 + Metformin Approved
First SGLT-2 + Metformin Approved See this week’s Item #1.
Read More »PreDiabetes Screening Test
PreDiabetes Screening Test Finally there’s a test that only focuses on PreDiabetes. At the recent AADE meeting, a new company came our way with a home laboratory test that can demonstrate whether a patient has prediabetes or even diabetes. It’s a mail-away finger-stick test that is 99.9% accurate. Now you can …
Read More »MannKind Partners with Sanofi to Market Afrezza
MannKind will get 35% of the profits while Sanofi is set to get 65% of profits on Afrezza. Afrezza was approved with a black box warning which states, "Acute bronchospasm has been observed in patients with asthma and COPD using Afrezza. Afrezza is contraindicated in patients with chronic lung disease such as asthma …
Read More »Implantable Molecular Device Produces Insulin
Swiss scientists have created an implantable molecular device with a sensor that measures blood pH levels and a gene feedback mechanism that produces the necessary amount of insulin if acidosis becomes a risk for type 1 diabetes patients. The molecular device was designed using various genes and proteins, and comprises a …
Read More »Excess Weight Associated with 10 Cancers
In a study using data from 5 million patients, researchers found that obese or overweight individuals had a higher risk of developing 10 common cancers. Leukemia and cancers of the uterus, gallbladder, kidney, cervix and thyroid rose linearly along with weight. Higher BMI was associated with a greater risk of …
Read More »FDA Approves J&J’s Invokamet Combo (SGLT-2 + Metformin)
The US Food and Drug Administration has approved Invokamet, a fixed-dose therapy combining Invokana (canagliflozin) and metformin…. Invokana, a member of the new class of drugs known as sodium glucose co-transporter 2 (SGLT2) inhibitors, was approved in the USA as a single agent in March 2013. The thumbs-up is based …
Read More »Should Non-diabetics Use Diabetes Drugs?
A study involving over 180,000 people showed that patients treated with metformin can live longer than non-diabetics….
Read More »The Importance of Control Solution
Control solution, used for ensuring the proper function of glucose meters, doesn’t appear to be a priority among physicians, pharmacists, or patients….
Read More »Early Insulin Delays Diabetes But Are There Negative Consequences?
One researcher comments, "Please don’t fall into this trap that you can prevent diabetes with insulin."…
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.